Browse the evidence

miR-27a and miR-27b suppress adipocyte differentiation by targeting PPARγ, and lower miR-27a expression in obese mice may be necessary for adipocyte hypertrophy.

miR-27a and miR-27b suppress fat cell differentiation by targeting PPARγ. Lower levels of miR-27a in obese mice suggest that suppressing these miRNAs might promote fat cell growth, while mimicking them could potentially reduce lipid storage.

Cellular reprogramming to induced pluripotent stem cells (iPSCs) can model progeroid syndromes and reveal epigenetic defects associated with premature aging, offering a platform for screening epigenetic therapeutics.

iPSC technology allows scientists to study aging at a cellular level by creating stem cells from patients with premature aging syndromes. This helps identify potential drug targets but is not a treatment available to patients today.

Excessive nitric oxide production, particularly via inducible NOS (iNOS) during inflammation, is cytotoxic, promotes oxidative stress, and impairs mitochondrial function, leading to cell death and organ failure.

While NO is beneficial in normal amounts, chronic inflammation can lead to excessive NO production that damages cells. Managing inflammation through lifestyle and medical care helps prevent this harmful excess.

IGF1 levels are positively associated with prostate cancer risk, while IGFBP3 levels are inversely associated, suggesting their potential as prognostic markers.

For men with prostate cancer, IGF1 and IGFBP3 levels may help predict outcomes. High IGF1 and low IGFBP3 are associated with worse prognosis.

In nonalcoholic fatty liver disease (NAFLD), the presence of hepatic cholesterol crystals within hepatocyte lipid droplets and the subsequent formation of Kupffer cell 'crown-like structures' around dead hepatocytes distinguish nonalcoholic steatohepatitis (NASH) from simple steatosis.

If you have fatty liver, simply reducing fat intake might not be enough if cholesterol crystallization is driving inflammation. The presence of cholesterol crystals and the resulting immune response (crown-like structures) are key markers of serious liver disease (NASH) versus simple fat accumulation. Managing this likely requires addressing the underlying metabolic drivers of cholesterol handling and inflammation, not just total fat intake.

Activation of the IL-4/STAT6 immune signaling pathway improves insulin sensitivity and glucose homeostasis by repressing hepatic PPARα-mediated fatty acid oxidation and reducing adipose tissue inflammation.

This research suggests that the type of immune response your body mounts matters for metabolic health. While chronic bacterial-type inflammation is linked to insulin resistance, specific immune pathways (like those triggered by allergies or parasitic responses) may actually improve how your body handles sugar and fat. This is a mechanistic finding in mice; it does not currently translate to a human treatment protocol.

Constitutive upregulation of the Nrf2 signaling pathway is a primary mechanism for extended healthspan and longevity in naturally long-lived species, acting as a master regulator of cytoprotection against oxidative stress, inflammation, and protein damage.

Focus on lifestyle factors that naturally activate the Nrf2 pathway, such as exercise and consuming phytochemicals found in plants (e.g., sulforaphane from broccoli, curcumin), rather than relying solely on antioxidant supplements. This supports the body's natural defense mechanisms against aging and disease.

Adverse environmental conditions during early somatic development (fetal/infancy) increase the lifelong risk of chronic diseases such as obesity, diabetes, and cardiovascular disease through persistent metabolic and physiological programming.

Your health trajectory is influenced by your early environment, not just your current habits. While you cannot change your birth weight or early nutrition, understanding this link helps explain why certain metabolic risks exist and underscores the importance of maintaining a healthy lifestyle to counteract early programming.

Maternal and neonatal nutritional status (both under- and over-nutrition) induces stable epigenetic modifications (DNA methylation, histone modification, miRNA) that program offspring susceptibility to metabolic syndrome, insulin resistance, and obesity in adulthood.

For expectant parents: Prioritize balanced nutrition (avoiding both severe restriction and excessive high-fat/sugar diets) during pregnancy and early infancy. This is not just about birth weight, but about programming the child's long-term metabolic health and reducing the risk of future obesity and diabetes through epigenetic mechanisms.

Metabolic disruptors can cause transgenerational inheritance of obesity and metabolic dysfunction, affecting offspring (F3 generation) who were never directly exposed to the chemical.

Be aware that your metabolic health may be influenced by your parents' and grandparents' environmental exposures. While you cannot change the past, you can protect your children by minimizing their exposure to plastics and environmental chemicals.

Administration of the bioactive peptide adropin34-76 improves glucose tolerance and insulin sensitivity in diet-induced obese mice by enhancing skeletal muscle insulin signaling and shifting fuel preference toward glucose oxidation.

This research suggests that the peptide hormone adropin can improve how the body processes glucose and insulin in obese individuals. It works by enhancing insulin signaling in muscles and shifting the body's fuel preference from fat to glucose. While this is a peptide therapy not yet available for general use, it highlights the importance of hormonal balance in metabolic health and offers a potential future therapeutic avenue for insulin resistance.

The efficacy of GIP-GLP-1 co-agonists may be explained by biased agonism and altered receptor internalization, which prevents the desensitization seen with pure GIP agonists.

The superior effect of co-agonists like tirzepatide may be due to their specific molecular design, which alters how receptors are signaled and internalized, preventing the 'shut down' (desensitization) that occurs with pure GIP agonists.

Intermittent fasting worsens glucose tolerance and induces beta-cell death in mice with lysosomal dysfunction (LAMP2 deficiency) or impaired autophagosome formation (BECN1 deficiency).

If you have underlying cellular recycling defects, fasting might damage your pancreas. Consult a doctor before trying IF if you have known metabolic disorders.

Shorter telomeres in tumor tissue (breast, colon, prostate) are associated with advanced disease state, faster progression, and poorer survival, whereas leukocyte telomere length (LTL) shows inconsistent associations with cancer risk.

If you have cancer, shorter telomeres in the tumor tissue often signal a more aggressive disease. However, a blood test for telomere length (LTL) is not yet a reliable way to predict if you will get cancer, as research findings are inconsistent. Focus on proven risk reduction strategies rather than LTL testing for cancer prediction.

Tomatidine extends lifespan and healthspan in C. elegans by inducing mitophagy through the SKN-1/Nrf2 pathway.

Tomatidine, found in unripe tomatoes, may support healthy aging by clearing damaged mitochondria. However, current evidence is limited to worms and cell cultures. No human dosage or safety data exists yet. Do not self-prescribe high doses based on this research.

Overexpression of the mitochondrial deacetylase SIRT3 protects hepatocytes from lipotoxicity by promoting both macroautophagy (lipophagy) and chaperone-mediated autophagy (CMA) through the activation of the AMPK-ULK1 pathway.

This research highlights that maintaining healthy mitochondrial function and NAD+ levels (via exercise, fasting, or metabolic health) may support SIRT3 activity, which in turn helps the liver clear excess fat through autophagy. It suggests that strategies improving metabolic flexibility are more effective than targeting single enzymes in isolation.

CTRP9 is a potent cardioprotective adipokine that attenuates acute ischemia/reperfusion injury and mitigates pathologic ventricular remodeling post-MI, primarily via PKA-dependent pathways.

CTRP9 is a protein produced by the heart and fat that helps protect the heart after a heart attack. While not yet a standard treatment, maintaining metabolic health may support natural CTRP9 levels, which help reduce scarring and improve heart function after injury.

The splicing shift toward ING1a over ING1b promotes cellular senescence and prevents apoptosis, contributing to the maintenance of the senescent state.

No direct human intervention recommended.

GLP-1 receptor stimulation attenuates the reward effects of psychostimulants (cocaine and amphetamine) and nicotine, suggesting a role for endogenous GLP-1 in curbing drug reward.

GLP-1 based therapies may reduce the reward of addictive substances like cocaine, amphetamine, and nicotine. This suggests a potential future use in addiction treatment, particularly for reducing the 'high' or craving associated with these substances. However, this is currently based on animal studies.

For individuals with obesity who fail to lose ≥2% body weight in the first 4 weeks of intensive behavioral treatment, adding phentermine (15.0 mg/day) significantly increases 24-week weight loss compared to continuing behavioral treatment with placebo.

If you have been doing intensive lifestyle changes for a month and haven't lost at least 2% of your body weight, adding phentermine (15 mg daily) to your plan can significantly boost your weight loss results compared to sticking with lifestyle changes alone. This approach helps early non-responders achieve clinically meaningful weight loss (≥5%) much more effectively. Regular monitoring of blood pressure and heart rate is recommended due to potential side effects.

Subcutaneous semaglutide (2.0 mg or higher, once weekly) produces significant weight loss and cardiometabolic improvements in adults with overweight or obesity, with efficacy increasing in patients with Class II obesity and higher dosages.

If you have overweight or obesity, subcutaneous semaglutide taken once weekly at a dose of 2.0 mg or higher is a highly effective treatment for weight loss. It works best when combined with lifestyle changes (diet and exercise). You can expect significant weight loss (nearly 9 kg on average in this analysis) and improvements in waist circumference and BMI. Patients with more severe obesity (Class II) tend to lose more weight. While gastrointestinal side effects like nausea are common, serious side effects are rare. The once-weekly schedule is preferred for adherence and safety over daily dosing.

AMG 133 (maridebart cafraglutide), a bispecific molecule combining a GIP receptor antagonist with a GLP-1 receptor agonist, produces pronounced, dose-dependent weight loss and improves metabolic parameters in adults with obesity.

AMG 133 is a new injectable medication for obesity that works by targeting two gut hormones (GLP-1 and GIP). In early clinical trials, it caused significant weight loss (up to 14.5% of body weight) with a dosing schedule of just one injection every four weeks. While it can cause temporary nausea or vomiting, these side effects are usually mild and go away quickly. It is currently in clinical trials and not yet widely available.

High-velocity, high-intensity progressive resistance training (power training) improves glycemic control (HbA1c) and insulin sensitivity in older adults with Type 2 Diabetes and metabolic syndrome.

If you have Type 2 Diabetes and are over 60, standard walking might not be enough. This study tests a specific type of weightlifting called 'power training' where you lift weights quickly (but safely) at about 80% of your max strength, three times a week. This approach aims to improve your blood sugar control and muscle function better than slow, light exercises. It requires professional supervision to ensure safety and proper progression.

High-intensity interval training (HIIT) significantly improves insulin sensitivity (fasting insulin and HOMA-IR) and cardiorespiratory fitness (VO2max) compared to moderate-intensity continuous training (MICT) in patients with diabesity.

If you have type 2 diabetes and are overweight, High-Intensity Interval Training (HIIT) may offer better improvements in insulin sensitivity and heart health than steady-state moderate exercise. HIIT involves short bursts of effort exceeding 80% of your max heart rate. It is time-efficient and can be adapted to your fitness level, making it a viable option even if you have physical limitations.